34 results
S-1/A
EX-10.3
CADL
Candel Therapeutics Inc
16 Jul 21
IPO registration (amended)
6:07am
Exhibit 10.3
CANDEL THERAPEUTICS, INC.
SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN
Purpose
This Senior Executive Cash Incentive Bonus Plan … and authority to administer and interpret the Incentive Plan.
Bonus Determinations
(a) Corporate Performance Goals. A Covered Executive may receive
S-1/A
EX-10.5.3
CADL
Candel Therapeutics Inc
16 Jul 21
IPO registration (amended)
6:07am
and state payroll withholding requirements in accordance with Company’s standard payroll practices (“Base Salary”).
2.2 Bonus.
(a) During Employment … . Employee shall be eligible to earn an annual performance bonus of up to 40% of her Base Salary (“Annual Bonus”). The Annual Bonus will be based upon
S-1/A
EX-10.5.1
CADL
Candel Therapeutics Inc
16 Jul 21
IPO registration (amended)
6:07am
. The Executive’s initial target annual incentive compensation shall be 50% percent of the Executive’s Base Salary plus, with respect to any bonus … payable in respect of the 2020 fiscal year and the 2021 fiscal year, any Signing Bonus (as defined below) paid in the relevant fiscal year for which
S-1/A
EX-10.5.2
CADL
Candel Therapeutics Inc
16 Jul 21
IPO registration (amended)
6:07am
public offering of the Company’s common stock.
2.2 Bonus.
(a) During Employment. Employee shall be eligible to earn an annual performance bonus … of up to 45% of his Base Salary (“Annual Bonus”). The Annual Bonus will be based upon the attainment by Employee of certain financial, clinical
10-K/A
2022 FY
CADL
Candel Therapeutics Inc
1 May 23
Annual report (amended)
8:01am
. Compensation for our executive officers is composed primarily of the following main components: base salary, bonus and equity incentives in the form … 31, 2022 and 2021.
Name and Principal
Position
Year
Salary
Bonus
($)(1)
Stock
Awards
($)(2)
Option
Awards
($)(2)
Non-Equity
Plan
Compensation
S-1/A
EX-10.5.4
g74dkjr0
16 Jul 21
IPO registration (amended)
6:07am
DEF 14A
e1b9w48lt1aflgrl7a
2 Sep 22
Definitive proxy
8:30am
8-K
hcwzb5dz27y 36nzys
7 Sep 22
Candel Therapeutics Announces Two Executive Leadership Appointments
8:02am
S-1/A
EX-10.1
58d6v
16 Jul 21
IPO registration (amended)
6:07am
S-1/A
EX-10.5.5
t93gilhl6vodtm0d5h
16 Jul 21
IPO registration (amended)
6:07am
10-K
EX-10.12
mduhb5at
29 Mar 22
Annual report
8:46am
S-1/A
p8git6t 6fg
16 Jul 21
IPO registration (amended)
6:07am
424B4
se6mtbptrns5ew0re
28 Jul 21
Prospectus supplement with pricing info
4:02pm
S-1
3tvpf1zrumac2 2c
25 Jun 21
IPO registration
5:28pm
DRS/A
oxh5wifa35c499ohuyqd
31 Mar 21
Draft registration statement (amended)
12:00am